Insys Therapeutics market cap is $3.1 m, and annual revenue was $82.08 m in FY 2018

Insys Therapeutics Gross profit (Q1, 2019)3.1 M

Insys Therapeutics Gross profit margin (Q1, 2019), %40%

Insys Therapeutics Net income (Q1, 2019)-123.8 M

Insys Therapeutics EBIT (Q1, 2019)-122.1 M

Insys Therapeutics Cash, 31-Mar-201936.5 M

Insys Therapeutics EV-21.2 M

Insys Therapeutics revenue was $82.08 m in FY, 2018

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Revenue | 99.3m | 222.1m | 330.8m | 242.3m | 140.7m | 82.1m |

| 124% | 49% | (27%) | |||

## Cost of goods sold | 12.7m | 22.6m | 28.9m | 25.4m | 20.6m | 10.8m |

## Gross profit | 86.6m | 199.5m | 301.9m | 216.9m | 120.1m | 71.3m |

| 87% | 90% | 91% | 90% | 85% | 87% |

## Sales and marketing expense | 29.2m | 58.1m | 80.7m | 69.7m | 48.9m | 31.4m |

## R&D expense | 8.5m | 33.1m | 55.3m | 73.9m | 63.0m | 57.6m |

## General and administrative expense | 16.4m | 44.3m | 64.0m | 62.1m | 67.6m | 39.3m |

## Operating expense total | 54.1m | 135.5m | 209.5m | 209.6m | 339.1m | 199.0m |

## EBIT | 32.6m | 64.0m | 92.4m | 7.3m | (219.0m) | (127.7m) |

| 33% | 29% | 28% | 3% | (156%) | (156%) |

## Interest expense | 928.0k | 153.0k | 538.0k | 1.1m | 1.8m | 1.3m |

## Interest income | 151.0k | 502.0k | 1.0m | 1.9m | 2.0m | |

## Pre tax profit | 31.6m | 64.2m | 93.0m | 8.4m | (217.2m) | (126.4m) |

## Income tax expense | (8.8m) | 26.2m | 34.5m | 834.0k | 10.8m | (1.9m) |

## Net Income | 40.4m | 38.0m | 58.5m | 7.6m | (228.0m) | (124.5m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 45.4m | 58.1m | 79.5m | 104.6m | 32.0m | 31.6m |

## Accounts Receivable | 16.3m | 26.5m | 48.5m | 21.5m | 12.6m | |

## Prepaid Expenses | 1.7m | 2.2m | 4.0m | 19.8m | 9.4m | |

## Inventories | 14.5m | 34.8m | 41.7m | 21.7m | 17.4m | 8.6m |

## Current Assets | 82.2m | 151.0m | 253.2m | 231.0m | 175.9m | 126.3m |

## PP&E | 10.1m | 29.9m | 38.4m | 43.2m | 55.2m | 52.1m |

## Total Assets | 100.6m | 215.1m | 351.2m | 356.1m | 279.1m | 192.5m |

## Accounts Payable | 16.6m | 27.5m | 36.4m | 27.4m | 30.4m | 50.9m |

## Current Liabilities | 21.1m | 45.7m | 88.9m | 78.6m | 207.2m | 106.9m |

## Total Debt | ||||||

## Total Liabilities | 21.1m | 49.5m | 97.5m | 86.5m | 215.8m | 235.6m |

## Common Stock | 5.0k | 354.0k | 719.0k | 719.0k | 736.0k | 744.0k |

## Preferred Stock | ||||||

## Additional Paid-in Capital | 168.5m | 216.4m | 245.7m | 256.5m | 278.4m | 292.5m |

## Retained Earnings | (89.0m) | (51.1m) | 7.4m | 12.7m | (215.4m) | (336.1m) |

## Total Equity | 79.5m | 165.7m | 253.7m | 269.6m | 63.3m | (43.1m) |

## Financial Leverage | 1.3 x | 1.3 x | 1.4 x | 1.3 x | 4.4 x | -4.5 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | 40.4m | 38.0m | 58.5m | 7.6m | (228.0m) | (124.5m) |

## Depreciation and Amortization | 1.8m | 2.5m | 5.3m | 6.2m | 7.3m | 7.6m |

## Accounts Receivable | (13.2m) | (10.2m) | (21.9m) | 26.6m | (859.0k) | 8.9m |

## Inventories | (7.4m) | (20.3m) | (6.9m) | 15.0m | 2.3m | 2.3m |

## Accounts Payable | 14.4m | 50.4m | 52.2m | (18.5m) | (11.6m) | 15.8m |

## Cash From Operating Activities | 24.2m | 49.7m | 100.9m | 58.9m | (60.7m) | (56.0m) |

## Purchases of PP&E | (5.1m) | (22.2m) | (13.8m) | (10.6m) | (16.7m) | (6.1m) |

## Cash From Investing Activities | (5.5m) | (69.9m) | (88.7m) | (22.0m) | (17.8m) | 53.4m |

## Short-term Borrowings | 11.9m | |||||

## Cash From Financing Activities | 26.3m | 32.9m | 9.3m | (11.7m) | 5.8m | 2.1m |

## Net Change in Cash | 45.0m | 12.7m | 21.4m | 25.1m | (72.6m) | (447.0k) |

## Interest Paid | 51.0k | |||||

## Income Taxes Paid | 991.0k | 3.0m | 15.4m | 10.7m | 2.1m | (13.4m) |

USD | Q1, 2013 |
---|---|

## Debt/Equity | -0.2 x |

## Debt/Assets | 0.5 x |

## Financial Leverage | -0.4 x |